Immix Biopharma (Immix Biopharma) Total Receivables

: $1.17 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Immix Biopharma's Total Receivables for the quarter that ended in Dec. 2023 was $1.17 Mil.

Immix Biopharma Total Receivables Historical Data

The historical data trend for Immix Biopharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Receivables

0.18

0.13

0.03

0.26

1.17

Immix Biopharma Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Receivables												0.26	0.32	0.30	0.65	1.17

Immix Biopharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Immix Biopharma Total Receivables Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Immix Biopharma (Immix Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064

Website

https://www.immixbio.com

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.

Executives

Jason Hsu	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Helen C. Adams	director	15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan	director	1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky	director, 10 percent owner	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Ilya M Rachman	director, officer: CEO and Chairman	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris	director, officer: Chief Financial Officer	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Sean Senn	10 percent owner	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin	officer: Scientific Co-Founder	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross	officer: CMO & Head of Clinical Dev.	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064